Clinical Trial

PTSD Treatment and Sleep

Study Description

Suvorexant and Sleep's Benefits to Therapeutic Exposure for Posttraumatic Stress Disorder

The purpose of this study is to examine effects of blocking the orexin system with suvorexant after exposure-based intervention for posttraumatic stress disorder (PTSD) on sleep, PTSD symptoms, and intersession habituation.

Location

Locations Selected Location

Methods

Pharmaceutical medication involved Pharmaceutical medication involved
Patients and healthy individuals accepted Patients and healthy individuals accepted

Drug - suvorexant

First in class orexin antagonist approved by the FDA for the treatment of insomnia

placebo

Pill with inactive ingredients

Additional Information

Official Study Title

Can Blocking the Orexin System Enhance Sleep's Benefits to Therapeutic Exposure for PTSD?

Clinical Trial ID

NCT02849548

ParticipAid ID

zbq57b